A citation-based method for searching scientific literature


List of co-cited articles
481 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
55

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Paul M Ridker, Brendan M Everett, Aruna Pradhan, Jean G MacFadyen, Daniel H Solomon, Elaine Zaharris, Virak Mam, Ahmed Hasan, Yves Rosenberg, Erin Iturriaga,[...]. N Engl J Med 2019
480
29


Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
684
16

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
15

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Paul M Ridker, Peter Libby, Jean G MacFadyen, Tom Thuren, Christie Ballantyne, Francisco Fonseca, Wolfgang Koenig, Hiroaki Shimokawa, Brendan M Everett, Robert J Glynn. Eur Heart J 2018
192
14

Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Ola Kleveland, Gabor Kunszt, Marte Bratlie, Thor Ueland, Kaspar Broch, Espen Holte, Annika E Michelsen, Bjørn Bendz, Brage H Amundsen, Terje Espevik,[...]. Eur Heart J 2016
153
12

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Aruna D Pradhan, Aaron W Aday, Lynda M Rose, Paul M Ridker. Circulation 2018
82
13

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Peter Duewell, Hajime Kono, Katey J Rayner, Cherilyn M Sirois, Gregory Vladimer, Franz G Bauernfeind, George S Abela, Luigi Franchi, Gabriel Nuñez, Max Schnurr,[...]. Nature 2010
12

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Yiran Guo, Christina Chung, Anne Peasey, Roman Pfister,[...]. Lancet 2012
607
12


Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Nadeem Sarwar, Adam S Butterworth, Daniel F Freitag, John Gregson, Peter Willeit, Donal N Gorman, Pei Gao, Danish Saleheen, Augusto Rendon, Christopher P Nelson,[...]. Lancet 2012
481
12

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
11

Low-dose colchicine for secondary prevention of cardiovascular disease.
Stefan M Nidorf, John W Eikelboom, Charley A Budgeon, Peter L Thompson. J Am Coll Cardiol 2013
432
10


Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
10

Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk S J Opstal, Salem H K The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink,[...]. N Engl J Med 2020
279
10

NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Alena Grebe, Florian Hoss, Eicke Latz. Circ Res 2018
224
8



Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
Brendan M Everett, Jan H Cornel, Mitja Lainscak, Stefan D Anker, Antonio Abbate, Tom Thuren, Peter Libby, Robert J Glynn, Paul M Ridker. Circulation 2019
184
8



The NLRP3 inflammasome in acute myocardial infarction.
Stefano Toldo, Antonio Abbate. Nat Rev Cardiol 2018
225
7

Inflammatory and Cholesterol Risk in the FOURIER Trial.
Erin A Bohula, Robert P Giugliano, Lawrence A Leiter, Subodh Verma, Jeong-Gun Park, Peter S Sever, Armando Lira Pineda, Narimon Honarpour, Huei Wang, Sabina A Murphy,[...]. Circulation 2018
109
7

Progress and challenges in translating the biology of atherosclerosis.
Peter Libby, Paul M Ridker, Göran K Hansson. Nature 2011
7


Immunity and Inflammation in Atherosclerosis.
Dennis Wolf, Klaus Ley. Circ Res 2019
262
7


The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
Gerardus P J van Hout, Lena Bosch, Guilielmus H J M Ellenbroek, Judith J de Haan, Wouter W van Solinge, Matthew A Cooper, Fatih Arslan, Saskia C A de Jager, Avril A B Robertson, Gerard Pasterkamp,[...]. Eur Heart J 2017
166
7



The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
Gonzalo J Martínez, David S Celermajer, Sanjay Patel. Atherosclerosis 2018
103
6

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Erin A Bohula, Robert P Giugliano, Christopher P Cannon, Jing Zhou, Sabina A Murphy, Jennifer A White, Andrew M Tershakovec, Michael A Blazing, Eugene Braunwald. Circulation 2015
180
6

Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.
Daniel H Solomon, Robert J Glynn, Jean G MacFadyen, Peter Libby, Tom Thuren, Brendan M Everett, Paul M Ridker. Ann Intern Med 2018
35
17


Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Claes Held, Harvey D White, Ralph A H Stewart, Andrzej Budaj, Christopher P Cannon, Judith S Hochman, Wolfgang Koenig, Agneta Siegbahn, Philippe Gabriel Steg, Joseph Soffer,[...]. J Am Heart Assoc 2017
98
6

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
6

All roads lead to IL-6: A central hub of cardiometabolic signaling.
Peter Libby, Viviane Zorzanelli Rocha. Int J Cardiol 2018
23
26

Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis.
Stephen Kaptoge, Sreenivasa Rao Kondapally Seshasai, Pei Gao, Daniel F Freitag, Adam S Butterworth, Anders Borglykke, Emanuele Di Angelantonio, Vilmundur Gudnason, Ann Rumley, Gordon D O Lowe,[...]. Eur Heart J 2014
325
6


Inflammation in atherosclerosis.
Peter Libby. Nature 2002
5

Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice.
Hirokazu Kirii, Tamikazu Niwa, Yasuhiro Yamada, Hisayasu Wada, Kuniaki Saito, Yoichiro Iwakura, Masahide Asano, Hisataka Moriwaki, Mitsuru Seishima. Arterioscler Thromb Vasc Biol 2003
515
5

Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway.
Anton Gisterå, Anna-Karin L Robertson, John Andersson, Daniel F J Ketelhuth, Olga Ovchinnikova, Stefan K Nilsson, Anna M Lundberg, Ming O Li, Richard A Flavell, Göran K Hansson. Sci Transl Med 2013
125
5

Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities.
Magnus Bäck, Arif Yurdagul, Ira Tabas, Katariina Öörni, Petri T Kovanen. Nat Rev Cardiol 2019
289
5

C-reactive protein levels and outcomes after statin therapy.
Paul M Ridker, Christopher P Cannon, David Morrow, Nader Rifai, Lynda M Rose, Carolyn H McCabe, Marc A Pfeffer, Eugene Braunwald. N Engl J Med 2005
5

Inflammation in atherosclerosis: from pathophysiology to practice.
Peter Libby, Paul M Ridker, Göran K Hansson. J Am Coll Cardiol 2009
5

Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke.
Charles C Esenwa, Mitchell S Elkind. Nat Rev Neurol 2016
124
5

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
Michelle L O'Donoghue, Ruchira Glaser, Matthew A Cavender, Philip E Aylward, Marc P Bonaca, Andrzej Budaj, Richard Y Davies, Mikael Dellborg, Keith A A Fox, Jorge Antonio T Gutierrez,[...]. JAMA 2016
135
5



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.